Gregory Egnaczyk, MD
Advanced Heart Failure and Transplant Cardiology · Cincinnati, OHNPI 1174513733
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $56,920 of the $62,133 with a category attached, or 91.6%. Abbott accounts for 88.9% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $29,903 and has fallen 97.1% since, to $862 in 2025.
Across 173 payments — averaging $359.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$55K
- Boston Scientific$5K
- Novartis$580
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$170
- Briohealth Solutions, Inc.$148
- Alnylam Pharmaceuticals Inc.$136
- plus $779 from 16 others
Across 386 payments — averaging $406.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$100K
- Medtronic$44K
- AstraZeneca$7K
- Abbott$6K
What the payments were for
- Consulting fees$56,92092%
- Travel & lodging$9452%
- Food & beverage$4,2687%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 45 | $55,205 |
| Boston Scientific | 9 | $5,114 |
| Novartis | 76 | $580 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $170 |
| Briohealth Solutions, Inc. | 1 | $148 |
| Alnylam Pharmaceuticals Inc. | 2 | $136 |
| Cvrx, Inc. | 3 | $105 |
| Sanofi | 1 | $104 |
| Amgen | 6 | $91 |
| AstraZeneca | 4 | $82 |
| Merck | 5 | $70 |
| Bayer | 3 | $62 |
| Novo Nordisk | 3 | $51 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $45 |
| Kestra Medical Technology Services, Inc. | 2 | $43 |
| Abiomed | 1 | $41 |
| Pfizer | 2 | $26 |
| Boehringer Ingelheim | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Nuwellis, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,133 in reported general payments places this provider in the 85th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 55 | $1,293,052 |
| EntrestoSacubitril/Valsartan | 978 | $984,515 |
| EliquisApixaban | 439 | $430,566 |
| JardianceEmpagliflozin | 410 | $417,647 |
| FarxigaDapagliflozin Propanediol | 334 | $301,124 |
| XareltoRivaroxaban | 139 | $163,483 |
| OpsumitMacitentan | 11 | $137,037 |
| VerquvoVericiguat | 117 | $98,896 |
| CamzyosMavacamten | 12 | $98,799 |
| OzempicSemaglutide | 54 | $59,121 |
| Repatha SureclickEvolocumab | 32 | $30,030 |
| WegovySemaglutide | 13 | $16,849 |
| MounjaroTirzepatide | 13 | $16,793 |
| Sildenafil Citrate | 70 | $16,751 |
| CorlanorIvabradine Hcl | 13 | $16,108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $26 | $1,723,618494 claims |
| NovartisEntresto | $580 | $984,515978 claims |
| Boehringer IngelheimJardiance | $17 | $417,647410 claims |
| AstraZenecaFarxiga, Brilinta | $82 | $310,755345 claims |
| Johnson & JohnsonXarelto | $13 | $163,483139 claims |
| MerckVerquvo | $70 | $98,896117 claims |
| Novo NordiskOzempic, Wegovy | $51 | $75,97067 claims |
| AmgenCorlanor | $91 | $16,10813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Cincinnati
- Eugene ChungCincinnati$297K
- Ankit BhatiaCincinnati$141K
- Rachel GarciaCincinnati$104K
- Sateesh KesariCincinnati$101K
- Sitaramesh EmaniCincinnati$87K
- Santosh MenonCincinnati$30K
- Umama GorsiCincinnati$20K
- Stephanie DunlapCincinnati$9K
- Mahyar PourriahiCincinnati$8K
- Juliane ViereckeCincinnati$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.